Business
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company
Proven immunology-focused executive and physician-scientist who has led companies from inception to IPO, driven multiple regulatory approvals, and helped build multi-billion-dollar therapeutic portfoliosBOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today a
About this update from Cue Biopharma, Inc.
[{"type":"image","alt":"Cue Biopharma, Inc.","displaySize":"","headline":null,"caption":"Cue Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":110,"url":"https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/AEf3jiTtKkyXrUHlPyUA7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1NA--/https://media.zenfs.com/en/globenewswire.com/2e66156a6e123e96f63fe86db58bbe09","width":300,"height":110}},"lazy":false},{"type":"text","content":"Proven immunology-focused executive and physician-scientist who has led companies from inception to IPO, driven multiple regulatory approvals, and helped build multi-billion-dollar therapeutic portfolios","length":203,"tagName":"p"},{"type":"text","content":"BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Shao-Lee Lin, M.D., Ph.D., as Chief Executive Officer, President and Director. Dr. Lin will succeed Lucinda Warren, Interim President and Chief Executive Officer.","length":492,"tagName":"p"},{"type":"text","content":"“Shao-Lee’s exceptional track record progressing breakthrough therapies from concept to clinic, combined with her disciplined approach to leading companies through growth, will be a massive step as we advance CUE-401 and establish a robust clinical pipeline,” said Pasha Sarraf, M.D., Ph.D., chairman of the board at Cue Biopharma. “The Board is confident in her ability, alongside a strong and experienced executive leadership team, to drive value creation as Cue Biopharma continues its evolution into a clinical stage company. Her appointment underscores the Board’s focus on accelerating the company’s strategy and realizing the full potential of its platform and pipeline.”","length":678,"tagName":"p"},{"type":"text","content":"Shao-Lee Lin, M.D., Ph.D., newly appointed Chief Executive Officer, commented: “Cue represents a unique opportunity to bring meaningful medicines to patients with the advancement towards Phase 1 of CUE-401, a molecule with the potential to disrupt autoimmune disease. We are also pleased to share today the ...